Sam Sematis - Equilibar

Sam Sematis

Production Manager

Production Manager Sam Sematis

Production Manager Sam Sematis has a strong background in quality and played an instrumental role in helping Equilibar develop a quality management system that meets the requirements of ISO 9001:2015.

Sam has worked in a variety of industries and has owned his own business. He is also a skilled artisan and has experience as a book conservator and a glass sculptor.

“Both glass blowing and book conservation involve great attention to detail as well as knowledge of science,” he says. “For example, the composition of paper in a book determines exactly what solutions can be used in its conservation. At Equilibar, the materials are different but the focus on details is the same.”

Sam’s widely diverse background also includes living in a tent on Maui for a year and being a professional poker player.

At Equilibar, Sam enjoys both the hands-on aspects of his job as well as the leadership aspects. “My very favorite part of the job is solving problems,” he adds. “I find it most rewarding and it gives me a sense of accomplishment. Plus, the people I work with are some of the most intelligent, fun, and interesting people I know. They are a great team, as well as great individuals.”

When he’s not at Equilibar, Sam enjoys taking his young children to the Western North Carolina Nature Center. “It’s one of the best places for our family to visit and support. They help injured animals and educate people, and it’s a great place to take a hike with small kids.”

Sam is a member of Equilibar’s tactical leadership team.

Equilibar News
PUK magazine cover with stainless steel device

Journal article focuses on oligonucleotide production using pressure control with built in dampener

Oligonucleotide drugs are made up of short sections of genetic sequences and are used to target disorders in the genetic code. The first drug of this type was used in 1998 during the AIDS epidemic.  Since then, the field has accelerated rapidly and today many oligonucleotide drugs are in clinical trials, promising improvements in treatment Read More

Read More